Advancing Psychedelic-inspired Medicines Through Clinical Trials

CLINICAL TRIALS

PRE-DISCOVERY

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2A

PHASE 2B

PHASE 3

MINDMED DEVELOP (Commercial Drug Development Programs)

Anxiety - Project Lucy

Anxiety - Project Lucy

PHASE 2A

18-MC

Substance Use Disorders

Substance Use Disorders

PHASE 2A

LSD Microdosing

Adult ADHD

Adult ADHD

PHASE 2A

MINDMED DISCOVER (R&D Collaborations)

University Hospital Basel

LSD Assisted Therapy

Cluster Headaches

Multiple Ongoing or Completed:
 on LSD, MDMA, DMT, Psilocybin

LSD Assisted Therapy

PHASE 2

Cluster Headaches

PHASE 2

Multiple Ongoing or Completed:
 on LSD, MDMA, DMT, Psilocybin

PHASE 1

Home hero image man sleeping foreground

We’re a New Kind of Pharma Company

Patients and therapists deserve care that transcends traditional symptom management cycles, advancing long-term mental healing.

View our approach

Our Healing Goes Beyond Just A Pill

01

Discover

Rigorous science of novel psychedelic compounds, therapies, and healing technologies in collaboration with leading institutions and researchers to make faster discoveries, together

02

Develop

Conducting clinical trials of psychedelic inspired medicines and experiential therapies within existing regulatory pathways to ensure the most effective & transformative healing experience possible

03

Deploy

We hold ourselves and our products to the highest levels of safety, efficacy, and accessibility so psychedelic inspired medicines and experiential therapies can one day reach patients in need

Quotation Marks

This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”

Shark Tank's Kevin O' Leary MindMed Investor

MindMed named one of 36 startups that could change the world

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

We have the right people for the right reasons.

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

Robert Barrow

Chief Executive Officer and Board Director

Miri Halperin Wernli, PhD

Executive President and Board Director

Cynthia Hu, JD

Chief Legal Officer & Corporate Secretary

Daniel R Karlin, MD MA

Chief Medical Officer

Dave Guebert

Chief Financial Officer

Robert Malenka, MD PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Member, Scientific Advisory Board Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Maria A Oquendo, MD PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Bryan L Roth, MD PhD

Professor of Pharmacology, University of North Carolina School of Medicine; Director of the National Institute of Mental Health Psychoactive Drug Screening Program

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine

Peter Gasser, MD

Clinical Advisor

Stanley D Glick, MD PhD

Scientific Advisor

Matthew W Johnson, PhD

Clinical Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Matthias Liechti, MD PhD

Scientific Collaborator & Advisor

Sarah McCallum, PhD

Associate Professor of Neuroscience and Experimental Therapeutics (DNET) at Albany Medical College

Natalie Wheeler, PhD

Medical Science Liaison with Dova Pharmaceuticals

John Rotrosen, MD

Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

Sarah Y Vinson, MD

Board Director, Member of Compensation, Nomination, and Governance Committees

Brigid Makes

Board Director, Chair of Audit/Finance Committee, Member of Compensation Committee, Member of Nomination and Governance Committee

JR Rahn

Co-Founder

Stephen L Hurst, JD

Co-Founder

Scott Freeman, MD

Co-Founder

Leonard Latchman

Co-Founder

Carrie Liao, CPA

VP, Corporate Controller & Accounting Principal